We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

36 hedge funds and large institutions have $185M invested in Xeris Biopharma Holdings in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 2

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

20% more funds holding

Funds holding: 30 → 36 (+6)

2.15% more ownership

Funds ownership: 48.45% → 50.6% (+2.1%)

0% more capital invested

Capital invested by funds: $184M → $185M (+$805K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
36
Holders Change
+6
Holders Change %
+20%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
10
Reduced
2
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.4M
2
BlackRock
BlackRock
New York
+$8.02M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$4.99M
4
Northern Trust
Northern Trust
Illinois
+$1.59M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.46M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$5.41M
2
BC
Broadfin Capital
New York
-$4.75M
3
FCM
Farallon Capital Management
California
-$3.03M
4
Neuberger Berman Group
Neuberger Berman Group
New York
-$2.18M
5
Millennium Management
Millennium Management
New York
-$1.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$43.9M – – –
RG
2
Redmile Group
California
$42.4M -$43 -2 -0%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$32.2M +$22.4M +1,031,231 +129%
O
4
OppenheimerFunds
New York
$17.6M – – –
ACH
5
ArrowMark Colorado Holdings
Colorado
$11.1M +$782K +36,034 +6%
SM
6
Sabby Management
Florida
$8.56M +$852K +39,252 +9%
BlackRock
7
BlackRock
New York
$6.93M +$8.02M +369,416 +1,478%
Federated Hermes
8
Federated Hermes
Pennsylvania
$5.27M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$4.48M +$4.99M +230,064 +920%
PA
10
Perceptive Advisors
New York
$3.53M -$5.41M -249,373 -55%
GIM
11
Granahan Investment Management
Massachusetts
$2.31M +$9.66K +445 +0.3%
Northern Trust
12
Northern Trust
Illinois
$1.29M +$1.59M +73,334 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$1.18M +$1.46M +67,233 New
State Street
14
State Street
Massachusetts
$1.11M +$1.37M +62,925 New
LCM
15
Landscape Capital Management
New Jersey
$1.08M – – –
PPA
16
Parametric Portfolio Associates
Washington
$526K +$178K +8,223 +38%
Deutsche Bank
17
Deutsche Bank
Germany
$263K +$326K +15,016 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$262K +$324K +14,914 New
Charles Schwab
19
Charles Schwab
California
$255K +$315K +14,491 New
Morgan Stanley
20
Morgan Stanley
New York
$235K +$275K +12,663 +1,751%
California State Teachers Retirement System (CalSTRS)
21
California State Teachers Retirement System (CalSTRS)
California
$176K +$217K +10,000 New
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$112K +$138K +6,351 New
AIG
23
American International Group
New York
$77K +$95.3K +4,390 New
TRCT
24
Tower Research Capital (TRC)
New York
$72K +$88.7K +4,088 New
Victory Capital Management
25
Victory Capital Management
Texas
$61K +$9.85K +454 +15%
1
2

XERS Hedge Fund Activity: Q3 2018 in Review

36 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2018, worth a combined $185M — up 0.44% from $184M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new XERS positions and 14 closed out — a net gain of 6 holders — while 10 added to existing stakes and 2 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $22.4M. The largest seller was Perceptive Advisors, cutting an estimated $5.41M.

  • 36 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2018, up from 30 in Q2 2018.
  • Funds reported $185M of Xeris Biopharma Holdings stock for Q3 2018, up 0.44% quarter-over-quarter.
  • 20 funds opened new Xeris Biopharma Holdings positions in Q3 2018 and 14 closed out, a net change of +6 holders.
  • The largest Xeris Biopharma Holdings buyer in Q3 2018 was Fidelity Investments, an estimated $22.4M added.
  • The largest Xeris Biopharma Holdings seller in Q3 2018 was Perceptive Advisors, an estimated $5.41M sold.

Based on aggregated 13F filings for Q3 2018.